Get the Stockscreener App
20.34
6.38%
1.22
After Hours:
19.94
-0.40
-1.97%
Aktis Oncology Inc stock is traded at $20.34, with a volume of 129.68K.
It is up +6.38% in the last 24 hours and down -7.55% over the past month.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
See More
Previous Close:
$19.12
Open:
$19.46
24h Volume:
129.68K
Relative Volume:
0.41
Market Cap:
$1.12B
Revenue:
$29.71M
Net Income/Loss:
$-69.15M
P/E Ratio:
-39.65
EPS:
-0.513
Net Cash Flow:
$-52.28M
1W Performance:
+4.04%
1M Performance:
-7.55%
6M Performance:
+54,577%
1Y Performance:
+54,577%
1-Day Range:
$19.20
$20.53
1-Week Range:
$18.08
$20.53
52-Week Range:
$14.72
$29.16
Aktis Oncology Inc Stock (AKTS) Company Profile
Name
Aktis Oncology Inc
Sector
Industry
Phone
978-237-4380
Address
17 DRYDOCK AVENUE, BOSTON, NC
Compare AKTS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
20.34 | 1.06B | 29.71M | -69.15M | -52.28M | -0.513 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | H.C. Wainwright | Buy |
| Feb-03-26 | Initiated | BofA Securities | Buy |
| Feb-03-26 | Initiated | JP Morgan | Overweight |
| Feb-03-26 | Initiated | Leerink Partners | Outperform |
| Feb-03-26 | Initiated | TD Cowen | Buy |
| Jan-04-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-06-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-24-23 | Initiated | B. Riley Securities | Buy |
| Feb-02-21 | Reiterated | Craig Hallum | Buy |
| Jan-15-21 | Reiterated | Craig Hallum | Buy |
| Sep-18-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-10-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-13-19 | Reiterated | Craig Hallum | Buy |
| Feb-05-19 | Reiterated | Craig Hallum | Buy |
| Feb-05-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Dec-18-18 | Initiated | Craig Hallum | Buy |
| Nov-30-18 | Initiated | Lake Street | Buy |
| Jun-22-18 | Initiated | Loop Capital | Buy |
| Feb-09-18 | Initiated | Drexel Hamilton | Buy |
View All
Aktis Oncology Inc Stock (AKTS) Latest News
A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound - Yahoo Finance
Top Premarket Gainers - Moomoo
Aktis Oncology reports promising first-in-human... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Aktis Oncology to Present Promising AKY-2519 Data Targeting B7-H3 Tumors at 2026 ASCO Annual Meeting - Quiver Quantitative
Aktis Oncology Reports First-in-Human Clinical Imaging and - GlobeNewswire
New cancer agent shows high tumor uptake, limited healthy exposure - Stock Titan
Top Cybin (HELP) Competitors 2026 - MarketBeat
Blue Owl discloses 5.92% stake in Aktis Oncology (AKTS) in Schedule 13G - Stock Titan
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - The Motley Fool
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - The Motley Fool
AKTS: Advancing miniprotein radioconjugates for cancer, with strong pipeline, partnerships, and cash runway - TradingView
AKTS: Miniprotein radiopharmaceuticals advance in oncology with strong clinical and financial momentum - TradingView
Bank of America Securities Reaffirms Their Buy Rating on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge - BioSpace
William Blair Maintains Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
TD Cowen Maintains Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
Aktis: Q1 Earnings Snapshot - KTVB
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 - The Manila Times
Aktis Oncology Q1 net loss widens on increased IPO-related expenses - TradingView
Aktis Oncology (NASDAQ: AKTS) boosts cash to $538.5M after IPO despite higher Q1 loss - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Aktis Oncology (NASDAQ: AKTS) boosts cash with IPO, posts wider Q1 loss - Stock Titan
Earnings Flash (AKTS) Aktis Oncology, Inc. Reports Q1 Revenue $3.2M - Moomoo
Cancer radiopharma firm Aktis adds $365M IPO cash, funds to 2029 - Stock Titan
Aktis Oncology to Present at the BofA Securities Health Care Conference - GlobeNewswire
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer By Investing.com - Investing.com India
William Blair Initiates Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
AKTS: AKY-2519 advances in Phase I-B trials for mCRPC and B7H3-expressing tumors, with key data ahead - TradingView
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer - Investing.com Australia
Aktis opens prostate cancer study as it broadens AKY-2519 testing - Stock Titan
Aktis Oncology Initiates Phase 1b Clinical Trial for - GlobeNewswire
Aktis Oncology starts Phase 1b trial of AKY-2519 for advanced prostate cancer targeting B7-H3 tumors - Pluang
UCB strikes up to $2.2B Candid deal, spotlighting Two River and Vida - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
This Hyperfine Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday - Sahm
William Blair Initiates Aktis Oncology(AKTS.US) With Buy Rating, Announces Target Price $32 - Moomoo
William Blair Initiates Aktis Oncology at Outperform - Moomoo
Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting (AKTS) - Seeking Alpha
Massachusetts biotech IPOs surge after years of drought - The Business Journals
Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price Jump - Yahoo Finance
Aktis Oncology prices IPO at $18 per share - MSN
Economics Weekly: Capacity Growth—It’s Different This Time - William Blair
Analysts Are Bullish on Top Healthcare Stocks: Aktis Oncology, Inc. (AKTS), Intuitive Surgical (ISRG) - The Globe and Mail
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Aktis Oncology to Present Clinical Data on AKY-2519 Targeting B7-H3 at 2026 ASCO Annual Meeting - Quiver Quantitative
Two ASCO posters give first look at how Aktis cancer drug moves in tumors - Stock Titan
Is Aktis (AKTS) stock forming a squeeze pattern (Buying Pressure) 2026-04-18Expert Momentum Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know - Yahoo Finance
Aktis Oncology appoints Glenn Gormley to board of directors By Investing.com - Investing.com India
Should I buy Aktis Oncology, Inc. (AKTS) - Zacks Investment Research
Director at Aktis Oncology (NASDAQ: AKTS) awarded 37,866 stock options - Stock Titan
Aktis Oncology Inc Stock (AKTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):